Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.

@article{JohnsonAnsah2013TolerabilityAE,
  title={Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.},
  author={Hyacinthe Johnson-Ansah and Joelle Guilhot and Philippe Rousselot and Delphine Rea and Laurence Legros and Françoise Rigal-Huguet and Franck Emmanuel Nicolini and F. -X. Mahon and Claude Preudhomme and François Guilhot},
  journal={Cancer},
  year={2013},
  volume={119 24},
  pages={4284-9}
}
BACKGROUND The pegylated form of interferon-α-2a (PegIFNa2a) in combination with imatinib has demonstrated a molecular improvement in patients with chronic-phase chronic myeloid leukemia. However, to the authors' knowledge, the appropriate dose of PegIFNa2a has not been established to date. METHODS In the French SPIRIT trial, the authors compared 2 initial doses of PegIFNa2a, taking into account an amendment that recommended reducing that dose from 90 μg/week to 45 μg/week because of… CONTINUE READING
6 Citations
21 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Similar Papers

Loading similar papers…